Pfizer announced on Thursday that it is progressing with the development of a once-daily weight loss pill, which it believes has the potential to be competitive in the GLP-1 market. Meanwhile, the U.S. Food and Drug Administration (FDA) declined to approve Novo Nordisk’s once-weekly insulin. Additionally, a report from the U.S. Federal Trade Commission (FTC) revealed that pharmacy benefit managers (PBMs) are increasing drug prices.
Here are these stories and more notable pharmaceutical news highlights from this week.